Mercia‘s sale of OXGENE has been described by CEO Dr Mark Payton as a ‘transformational event’. It is great example of how our EIS fund and our PLC’s balance sheet work together to provide superior returns.
Watch as Dr. Mark Payton and Dr. Paul Mattick discuss OXGENE’s growth journey and how its sale reaffirms the significant opportunity and value creation potential offered by Mercia’s ‘fund first’ hybrid investment model.